ONCT — Oncternal Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.56m
- -$13.02m
- $0.79m
Oncternal Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Oncternal Therapeutics Q2 net income USD -8.966 million
Oncternal Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Oncternal Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Oncternal Therapeutics gains as dosing begins in cancer therapy trial
Brief: Oncternal Therapeutics Announces First Patient Dosed In Phase 1/2 Study Of ROR1
Oncternal Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Oncternal Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Oncternal Therapeutics To Provide Business Update And Report First Quarter 2023 Financial Results
Brief: Oncternal Therapeutics Inc - On April 4, Received Notice From Nasdaq That Co Is Not Been In Compliance With Minimum Bid Price Requirement
U.S. STOCKS ON THE MOVE-AMC Entertainment, Trilogy Metals, Nogin
U.S. STOCKS ON THE MOVE-Duckhorn Portfolio, BullFrog AI, VBI Vaccines
Oncternal Therapeutics hits record low on halting cancer therapy studies
U.S. STOCKS ON THE MOVE-Acuity Brands, Cardlytics, Tiziana
U.S. STOCKS ON THE MOVE-Etsy, Oncternal Therapeutics, Tesla
Oncternal Therapeutics down on halting some cancer therapy studies
Oncternal Therapeutics slumps on pausing studies of some cancer therapies
Oncternal Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Oncternal Therapeutics Announces Fourth Quarter And Full Year 2022 Financial Results